The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF V600E mutation

被引:0
|
作者
Rossi, Esther Diana [1 ]
Bizzarro, Tommaso [1 ]
Granja, Sara [2 ,3 ]
Martini, Maurizio [1 ]
Capodimonti, Sara [1 ]
Luca, Emilia [1 ]
Fadda, Guido [1 ]
Lombardi, Celestino Pio [4 ]
Pontecorvi, Alfredo [5 ]
Larocca, Luigi Maria [1 ]
Baltazar, Fatima [2 ,3 ]
Schmitt, Fernando [6 ,7 ,8 ]
机构
[1] Catholic Univ Sacred Heart Rome, Div Anat Pathol, Milan, Italy
[2] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga, Portugal
[3] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal
[4] Univ Cattolica Sacro Cuore, Div Endocrine Surg, Milan, Italy
[5] Univ Cattolica Sacro Cuore, Div Endocrinol, Milan, Italy
[6] Med Fac Univ, Porto, Portugal
[7] Inst Pathol Mol Immunol Porto, Porto, Portugal
[8] Lab Natl Sante Luxembourg, Luxembourg, Luxembourg
关键词
Liquid-based cytology; Thyroid lesions; PTC; Plump cells; MCTs; BRAF(V600E) mutation; LIQUID-BASED CYTOLOGY; ASPIRATION BIOPSIES; MALIGNANT-MELANOMA; PROGNOSTIC VALUE; BRAF(V600E); CANCER; CELLS; IMMUNOHISTOCHEMISTRY; IMPACT; CD147;
D O I
10.1007/s12020-016-1044-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BRAF (V600E) mutation, usually performed by DNA techniques, is one of the most common diagnostic markers in papillary thyroid carcinoma. Few papers have demonstrated that plump cells (eosinophilic cytoplasms and papillary thyroid carcinoma nuclei) and peculiar sickle-shaped nuclei represent morphological features of BRAF (V600E) on papillary thyroid carcinomas. These features seem to be linked to glycolytic phenotype whereby monocarboxylate transporters 1-4 are hypothesized to have a dominant role as lactate transporters. We investigated the association between these morphological features and monocarboxylate transporters 1 and 4 in 48 cyto-histological samples diagnosed as "positive for malignancy-favoring papillary thyroid carcinoma". These cases were processed with liquid-based cytology and underwent BRAF (V600E) mutational analysis (pyrosequencing) on liquid-based cytology and monocarboxylate transporters immunostaining on histology. The expression of monocarboxylate transporter 1, monocarboxylate transporter 4, glucose trasporter-1 and carbonic anhidrase were scored semi-quantitatively with expression from 0 to 3+ (strong positivity). The 33 mutated and 15 wild type cases showed 100 % cyto-histological concordance. The cytological evaluation revealed plump cells and sickle nuclear shape in 100 % mutated cases. Monocarboxylate transporter 1 yielded 76 % positivity in the mutated cases especially in both the plump cells and sickle-shaped nuclei, whereas the wild types showed 13.3 % positive monocarboxylate transporter 1 (p = 0.00013). Monocarboxylate transporter 4 resulted in 100 % positivity in mutated and 40 % in wild types (p < 0.005). Furthermore, 20 % of the wild types showed weak monocarboxylate transporter 1 nuclear expression associated to a less aggressive behavior. The analysis of glucose trasporter-1 and carbonic anhidrase did not highlight any statistical significance (p > 0.05). This is the first report analyzing the association between monocarboxylate transporter expression and the morphological features of BRAF (V600E) mutated papillary thyroid carcinomas suggesting the possible involvement of lactate in the morphological features.
引用
收藏
页码:379 / 387
页数:9
相关论文
共 50 条
  • [31] BRAF V600E MUTATION STATUS AND ASSOCIATED HISTOPATHOLOGY FEATURES IN PAPILLARY THYROID CARCINOMA: A COMPARISON OF NEW CALEDONIA AND AUSTRALIAN POPULATIONS
    Dy, Veronica
    Lie, Triyana
    Woolnough, Catherine
    Tubb, Jessie
    Dubourdieu, Dominique
    Damiens, Viviene
    McLennan, Susan
    Chua, Elizabeth
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 32 - 32
  • [32] BRAF(V600E) mutation and the biology of papillary thyroid cancer
    Frasca, F.
    Nucera, C.
    Pellegriti, G.
    Gangemi, P.
    Attard, M.
    Stella, M.
    Loda, M.
    Vella, V.
    Giordano, C.
    Trimarchi, F.
    Mazzon, E.
    Belfiore, A.
    Vigneri, R.
    ENDOCRINE-RELATED CANCER, 2008, 15 (01) : 191 - 205
  • [33] Braf V600E mutation analysis in low and intermediate risk papillary thyroid carcinoma
    Lopez Villar, I.
    Navarro Martinez, T.
    Jane Soler, P.
    Bonilla Plaza, J.
    Martinez Lorca, A.
    Perez Iruela, J.
    Orduna Diez, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S71 - S72
  • [34] Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma
    Zagzag, Jonathan
    Pollack, Aron
    Dultz, Linda
    Dhar, Shumon
    Ogilvie, Jennifer B.
    Heller, Keith S.
    Deng, Fang-Ming
    Patel, Kepal N.
    SURGERY, 2013, 154 (06) : 1199 - 1204
  • [35] BRAF expression is associated with poor survival in colorectal cancers independent of BRAF (V600E) mutation
    Yang, Mingli
    Schell, Michael J.
    Yeatman, Timothy J.
    CANCER RESEARCH, 2019, 79 (13)
  • [36] Correlation of the Expression of BRAF V600E Mutation With Various Phenotypic Expressions of Thyroid Neoplasms
    Harikrishnan, Volga
    Kumari, Shantha
    Ramkumar, Subramaniam
    Sankaran, Ramalingam
    Ramalingam, Sudha
    Sairam, Thiagarajan
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (06)
  • [37] BRAF V600E mutation detection by immunohistochemistry in colorectal carcinoma
    Affolter, Kajsa
    Samowitz, Wade
    Tripp, Sheryl
    Bronner, Mary P.
    GENES CHROMOSOMES & CANCER, 2013, 52 (08): : 748 - 752
  • [38] BRAF V600E Does Not Predict Aggressive Features of Pediatric Papillary Thyroid Carcinoma
    Givens, Daniel J.
    Buchmann, Luke O.
    Agarwal, Archana M.
    Grimmer, Johannes F.
    Hunt, Jason P.
    LARYNGOSCOPE, 2014, 124 (09): : E389 - E393
  • [39] BRAF V600E Gene Mutation Is Associated With Bilateral Malignancy of Papillary Thyroid Cancer
    Liu, Zhuoran
    Lv, Tian
    Xie, Cong
    Di, Zhongmin
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2018, 356 (02): : 130 - 134
  • [40] ASO Author Reflections: Is BRAF V600E Mutation Associated with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma?
    Hon-Fan Lai
    Jen-Fan Hang
    Jui-Yu Chen
    Annals of Surgical Oncology, 2024, 31 : 3974 - 3975